{"id":759,"date":"2026-02-25T11:34:35","date_gmt":"2026-02-25T11:34:35","guid":{"rendered":"https:\/\/thesporereport.com\/?p=759"},"modified":"2026-02-25T12:01:00","modified_gmt":"2026-02-25T12:01:00","slug":"common-side-effects-mushrooms-vs-big-pharma","status":"publish","type":"post","link":"https:\/\/thesporereport.com\/?p=759","title":{"rendered":"Common Side Effects: Mushrooms Vs Big Pharma"},"content":{"rendered":"\n

I’ve been watching Common Side Effects<\/em>, a breathtaking animated sci-fi satire about a quirky naturalist called Marshall who stumbles upon a hallucinogenic mushrooms that is capable of healing any ailment. <\/p>\n\n\n\n

Marshall shares this discovery with Frances, a former classmate now embedded in the pharma giant Reutical. As a result, Big Pharma, the DEA, and assorted institutional interests become aware that this specimen could change the world, so they try to end its existence.<\/p>\n\n\n\n

I’ve been thinking about why it resonates so deeply right now. And I think it has something to do with a shift in consciousness that is currently underway. Let me try and explain.<\/p>\n\n\n\n

The pharmaceutical model <\/h3>\n\n\n\n

Modern pharmaceutical science is, by any honest accounting, one of the great achievements of the twentieth century. Antibiotics, antivirals, surgical anaesthesia, insulin. The list of genuine miracles is a long one. But the model that produced these breakthroughs carries within it certain structural assumptions that have become increasingly difficult to ignore.<\/p>\n\n\n\n

The dominant paradigm is reductionist by design. Identify a single molecular target – a receptor, an enzyme, a pathway – and design a compound that modulates it with precision. This approach has obvious advantages. It produces measurable outcomes, it generates patentable intellectual property, and it lends itself to the kind of controlled clinical trials that regulatory bodies require. The entire architecture of drug development, from bench research through to FDA approval, is built around the idea that a medicine is a molecule that does one specific thing to one specific target.<\/p>\n\n\n\n

The trouble is that biology doesn’t work this way. Living systems are not machines with discrete, independent components. They are layered, adaptive, deeply interconnected networks in which a change to one element ripples outward in ways that are often unpredictable and sometimes paradoxical. The human body maintains itself through constant regeneration, feedback, and dynamic equilibrium. These processes resist the kind of linear, cause-and-effect logic that single-target pharmacology assumes. This is why drugs so frequently come with long lists of side effects.<\/p>\n\n\n\n

None of this is to say that targeted pharmaceuticals are useless. Many of them are life-saving and irreplaceable. But there is a growing recognition among researchers, clinicians, and patients that the reductionist model has become so dominant that it has crowded out other ways of thinking about medicine. Ways that may, in certain contexts, be more aligned with how living systems actually function.<\/p>\n\n\n\n

Mushrooms <\/h3>\n\n\n\n

This is where fungi become interesting, and where the conversation moves well beyond the domain of folk remedies and wellness marketing.<\/p>\n\n\n\n

Mushrooms and their mycelial networks have been producing bioactive compounds for hundreds of millions of years, long before humans existed to categorise them. These compounds did not evolve to hit single molecular targets. They evolved within ecosystems, in dialogue with bacteria, viruses, competing fungi, plant root systems, and soil chemistry. As a result, many of them act on the body in ways that are broad-spectrum and multi-modal, modulating several pathways simultaneously rather than forcing a single lever.<\/p>\n\n\n\n

At the cellular level, several mushroom-derived compounds interact directly with mitochondria. Mitochondria are the organelles responsible for cellular energy production, metabolic regulation, and, crucially, the signalling cascades that govern inflammation, apoptosis (programmed cell death), and oxidative stress. <\/p>\n\n\n\n

Compounds like the triterpenes found in Ganoderma lucidum<\/em> (reishi) and the cordycepin produced by Cordyceps militaris<\/em> have been shown in preclinical research to influence mitochondrial membrane potential, modulate ATP production, and regulate the NF-\u03baB inflammatory pathway. Beta-glucans, perhaps the most extensively studied class of mushroom polysaccharides, activate innate immune cells (macrophages, dendritic cells, natural killer cells) through pattern-recognition receptors like Dectin-1 and complement receptor 3, effectively priming the immune system’s own surveillance and response capacity rather than overriding it.<\/p>\n\n\n\n

What is striking about these mechanisms is their character. They tend to be modulatory rather than suppressive or stimulatory in a single direction. The immune system is nudged toward greater vigilance and adaptability, metabolic pathways are supported rather than hijacked, and inflammatory responses are calibrated rather than bluntly silenced. <\/p>\n\n\n\n

This is a fundamentally different pharmacological philosophy from the one that dominates modern drug development, and it raises a question that the field has been slow to ask: what if some of these compounds represent first-principle medicines – agents that work with the body’s own regenerative and regulatory systems rather than overriding them?<\/p>\n\n\n\n

The evidence<\/h3>\n\n\n\n

A 2018 review<\/a> published in ResearchGate<\/em> by researchers surveying the pharmacological potential of fungi describes mushrooms as “a major untapped source of future medicines” (what the authors term “mushroompharmaceuticals”). The review catalogues an impressive range of bioactive effects demonstrated in laboratory and animal studies: antioxidant, antitumour, antiviral, antimicrobial, immunomodulatory, anti-inflammatory, and analgesic properties spread across dozens of species, from the familiar (Lentinus edodes<\/em>, shiitake; Hericium erinaceus<\/em>, lion’s mane) to the less well known (Laetiporus sulphureus<\/em>, Meripilus giganteus<\/em>, Schizophyllum commune<\/em>).<\/p>\n\n\n\n

The antimicrobial findings are particularly noteworthy in the context of one of modern medicine’s most urgent crises. Antibiotic resistance represents a genuine civilisational threat. One that the existing pharmaceutical pipeline is poorly equipped to address, in part because new antibiotics are not particularly profitable to develop. <\/p>\n\n\n\n

Mushroom extracts and isolated compounds have demonstrated in vitro<\/em> activity against a wide range of bacteria, yeasts, and pathogenic fungi, with some showing anti-biofilm and anti-quorum sensing effects – mechanisms that target the cooperative behaviours bacteria use to become more virulent and resistant. This is a different strategy from conventional antibiotics, which typically attack the organism directly and thereby exert the evolutionary selection pressure that drives resistance.<\/p>\n\n\n\n

On pain relief, the review describes preclinical evidence that compounds including beta-glucans and fucogalactans from species like Pleurotus pulmonarius<\/em>, Inonotus obliquus<\/em> (chaga), and Cordyceps militaris<\/em> may reduce inflammatory pain through pathways distinct from those targeted by opioids or NSAIDs.<\/p>\n\n\n\n

The honest caveat, which any serious discussion must include, is that the vast majority of this evidence is preclinical. In vitro<\/em> studies and animal models tell us that something interesting is happening, but they do not tell us how these compounds will behave in the irreducible complexity of a living human body. Clinical trials in humans remain rare. The leap from promising laboratory finding to validated therapeutic is enormous, and the history of medicine is littered with compounds that looked extraordinary in a petri dish and proved disappointing or dangerous in practice.<\/p>\n\n\n\n

And yet. The question is not whether mushroom-derived compounds are ready to replace established pharmaceuticals tomorrow. The question is whether the structures of modern drug development are systematically biased against the kind of multi-target, synergistic, ecologically evolved agents that fungi produce. The answer, by any reasonable assessment, is yes. The incentive structures of pharmaceutical capitalism select for a particular type of medicine, and it is worth considering what falls outside the beam of that searchlight.<\/p>\n\n\n\n

From mechanical to living<\/h3>\n\n\n\n

I think there is a broader shift underway, one that extends beyond pharmacology into how we understand health itself. For much of the twentieth century, the dominant metaphor for the body was the machine. An extraordinarily complex machine, certainly, but a machine nonetheless, with parts that could be isolated, measured, replaced, and optimised. This metaphor was enormously productive. It gave us organ transplants, joint replacements, and the conceptual framework for most of modern surgery and pharmaceutical intervention.<\/p>\n\n\n\n

But metaphors shape what we can see, and what we cannot. A machine metaphor directs attention toward breakdown and repair, toward the identification of faulty components and the engineering of targeted fixes. It is less useful for understanding the processes by which living systems maintain themselves over time. It doesn’t account for the constant cellular turnover, the immune system’s ongoing negotiation between self and other, the gut microbiome’s influence on mood and cognition, the mitochondrial dynamics that govern how we age. These are not problems of broken parts. Rather, they are emergent properties of living networks.<\/p>\n\n\n\n

Mushrooms, and the mycelial networks from which they fruit, offer a rather elegant counter-metaphor. A mycelial network is decentralised, adaptive, and regenerative. It processes information, redistributes resources, responds to environmental stress, and maintains its own integrity without any central command structure. It is, in a meaningful sense, intelligent. Though its intelligence is distributed, relational, and context-sensitive in ways that resist the mechanistic frameworks we most readily reach for.<\/p>\n\n\n\n

The shift I’m describing – from mechanical to living, from centralised to distributed, from reductionist to ecological – is not a rejection of science. If anything, it is a deepening of scientific thinking, a willingness to take seriously the complexity that earlier models were forced, by methodological necessity, to bracket. The tools are finally beginning to catch up with the reality: systems biology, network pharmacology, metabolomics, and microbiome research are all, in their different ways, attempting to understand the body as the dynamic, interconnected, living system it actually is.<\/p>\n\n\n\n

Common Side Effects<\/em> <\/h3>\n\n\n\n

What Common Side Effects<\/em> captures, through the imperfect vessel of its narrative, is the tension between these two ways of seeing. Marshall’s relationship with the Blue Angel mushroom is intuitive, embodied, and deeply personal. Reutical’s interest in it is extractive, focusing on how to isolate the active compound, patent it, control it, and ultimately profit from it. <\/p>\n\n\n\n

The show does not pretend that Marshall’s approach is without problems; he is reckless, sometimes selfish, and his instinct to share the mushroom freely runs up against real questions about safety, dosage, and equitable distribution. But the show is clear-eyed about where the deeper danger lies. In a system that has become so efficient at converting healing into profit that it can no longer recognise healing when it takes a form that resists commodification.<\/p>\n\n\n\n

By its final episodes, Common Side Effects<\/em> arrives at something quietly radical – the suggestion that the way we think about cures may matter as much as the cures themselves. That a medicine embedded in relationship, in ecology, in the messy particularity of living systems, offers something that a molecule in a capsule, however effective, cannot fully replicate. This is the insight that the show circles around, and that the emerging science of mushroom pharmacology, with all its caveats, seems to be converging on from the other direction.<\/p>\n\n\n\n

Perhaps the most important thing fungi have to teach us is not any particular compound or therapeutic application, but something about the nature of health itself. That it is not a state to be engineered from the outside, but a capacity to be supported from within. That the body, like a forest, already knows how to heal, and that the most profound medicines may be the ones that remember this.<\/p>\n","protected":false},"excerpt":{"rendered":"

I’ve been watching Common Side Effects, a breathtaking animated sci-fi satire about a quirky naturalist called Marshall who stumbles upon a hallucinogenic mushrooms that is capable of healing any ailment. Marshall shares this discovery with Frances, a former classmate now embedded in the pharma giant Reutical. As a result, Big Pharma, the DEA, and assorted […]<\/p>\n","protected":false},"author":1,"featured_media":762,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"iawp_total_views":475,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/posts\/759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thesporereport.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=759"}],"version-history":[{"count":4,"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/posts\/759\/revisions"}],"predecessor-version":[{"id":764,"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/posts\/759\/revisions\/764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thesporereport.com\/index.php?rest_route=\/wp\/v2\/media\/762"}],"wp:attachment":[{"href":"https:\/\/thesporereport.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thesporereport.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thesporereport.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}